Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Laboratory and Clinical Medicine

• Publication date

  2003-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0022-2143(03)00137-9PMID 14647034
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy

  2004cited by this paper
• ADVANCES IN THE DEVELOPMENT OF A RELIABLE ASSAY FOR THE MEASUREMENT OF STOOL DECAY-ACCELERATING FACTOR IN THE DETECTION OF COLORECTAL CANCER

  2002cited by this paper
• Enhanced expression of decay‐accelerating factor and CD59/homologous restriction factor 20 in intestinal metaplasia, gastric adenomas and intestinal‐type gastric carcinomas but not in diffuse‐type carcinomas

  2002cited by this paper
• Improvements in the measurement of stool decay-accelerating factor in the detection of colorectal cancer.

  2002cited by this paper
• Polymorphic expression of decay‐accelerating factor in human colorectal cancer

  2001cited by this paper
• Epidermal growth factor induces expression of decay-accelerating factor in human colonic cancer cells via the mitogen-activated protein kinase pathway.

  2001cited by this paper
• Decay-accelerating factor: CD55, DAF

  2000cited by this paper
• Cytokine‐stimulated release of decay‐accelerating factor (DAF; CD55) from HT‐29 human intestinal epithelial cells

  1998cited by this paper
• Detection of decay-accelerating factor in stool specimens of patients with colorectal cancer.

  1995cited by this paper
• Streptolysin-O induces release of glycosylphosphatidylinositol-anchored alkaline phosphatase from ROS cells by vesiculation independently of phospholipase action.

  1995cited by this paper
• Release of GPI‐anchored membrane proteins by a cell‐associated GPI‐specific phospholipase D.

  1994cited by this paper
• Distribution of complement regulatory proteins, decay-accelerating factor, CD59/homologous restriction factor 20 and membrane cofactor protein in human colorectal adenoma and cancer.

  1994cited by this paper
• Factors affecting the ability of glycosylphosphatidylinositol-specific phospholipase D to degrade the membrane anchors of cell surface proteins.

  1991cited by this paper
• Phosphatidylinositol-specific phospholipases C from Bacillus cereus and Bacillus thuringiensis.

  1991cited by this paper
• Biosynthesis of carcinoembryonic antigen (CEA) gene family members expressed in human tumor cell lines: evidence for cleavage of the glycosyl phosphatidyl inositol (GPI) anchor by GPI-PLC and GPI-PLD.

  1991cited by this paper
• Decay-accelerating factor: biochemistry, molecular biology, and function.

  1989cited by this paper
• Decay-Accelerating Factor: Biochemistry, Molecular Biology, and Function

  1989cited by this paper
• Ectoenzymes of the kidney microvillar membrane. Affinity purification, characterization and localization of the phospholipase C-solubilized form of renal dipeptidase.

  1989cited by this paper
• Purification of a glycosyl-phosphatidylinositol-specific phospholipase D from human plasma.

  1989cited by this paper
• A phospholipase D specific for the phosphatidylinositol anchor of cell-surface proteins is abundant in plasma.

  1988cited by this paper
• Structural and functional roles of glycosyl-phosphatidylinositol in membranes.

  1988cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins

  1987cited by this paper
• Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids

  1987cited by this paper
• A glycan-phosphatidylinositol-specific phospholipase D in human serum.

  1987cited by this paper
• The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb

  1987cited by this paper
• Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein

  1986cited by this paper
• Biosynthesis and glycosylation of the human complement regulatory protein decay-accelerating factor.

  1986cited by this paper
• Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns.

  1985cited by this paper
• Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.

  1982cited by this paper
• Phosphatidylinositol-specific phospholipase C from Staphylococcus aureus.

  1981cited by this paper
• [85] Phosphatidylinositol-specific phospholipase C from Staphylococcus aureus

  1981cited by this paper
• Phase separation of integral membrane proteins in Triton X-114 solution.

  1981cited by this paper
• Shedding from normal and cancer-cell surfaces.

  1980cited by this paper
• Shedding from the cell surface of normal and cancer cells.

  1980cited by this paper

• EXPRESSION PATTERNS OF THE HUMAN RIBOSOMAL PROTEIN GENES eL14 AND uS19 IN COLON CANCER IS DEPENDENT ON THE TYPE AND STAGE OF THE CANCER CELL

  2020cites this paper
• Tumor Microenvironment and Cellular Stress

  2014cites this paper
• The role of complement in tumor growth.

  2014cites this paper
• A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

  2011cites this paper
• Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer

  2008cites this paper
• Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection.

  2008cites this paper
• Complement decay accelerating factor (DAF)/CD55 in cancer

  2006cites this paper
• A homologue of the Drosophila headcase protein is a novel tumor marker for early-stage colorectal cancer.

  2006cites this paper
• The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy

  2006cites this paper
• Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies.

  2006cites this paper
• Stool screening for colorectal cancer: molecular approaches.

  2005cites this paper
• Potential of faecal RNA in diagnosing colorectal cancer.

  2005cites this paper
• Stool decay‐accelerating factor as a marker for monitoring the disease activity during leukocyte apheresis therapy in patients with refractory ulcerative colitis

  2005cites this paper